Long-term Growth in Congenital Adrenal Hyperplasia
- 90 Downloads
To retrospectively assess growth of children with congenital adrenal hyperplasia (CAH) with special reference to puberty and to assess longitudinal growth and final height of subset of children with CAH.
A retrospective analysis of 30 children (14 boys) with classic CAH (11 salt wasters, 19 simple virilisers) followed up for a mean duration of 9.9 ± 2.4 y (Study period December 2002 through December 2016) was performed. Height Z scores, target height Z scores, height velocities and laboratory parameters were analysed.
Children were treated with hydrocortisone in a mean dose of 15.7 ± 3.3 mg/m2/d. Mean 17-hydroxy progesterone in boys and girls were 10.8 ± 6.7 ng/ml and 11.3 ± 9.3 ng/ml respectively. Fifteen children (7 boys) developed central precocious puberty at mean age of 7.6 ± 1.8 y and 13 were treated with GnRH analogues for 3.5 y. Of all patients, 18 (10 girls, 8 boys) reached final height at a mean age of 14.2 ± 1.6 y. Mean final height achieved was 158.0 ± 8.5 cm in boys [target height (TH) -165.5 ± 3.8 cm] and in girls it was 149.9 ± 6.7 cm [target height (TH) 154.7 ± 6.4 cm]. Final height standard deviation scores (SDS) for boys and girls were − 2.06 ± 1.1 (TH-SDS -1.06 ± 0.5) and − 1.47 ± 1.1 (TH-SDS -0.56 ± 1.2) respectively and were not significantly different from target height Z scores (p > 0.05). Growth velocity was attenuated during pubertal years.
Monitoring growth and puberty in children with CAH is critical for optimizing final height.
KeywordsCAH Growth Adult height
VK: Design and concept of the study, design, revision and final submission of manuscript; AM: Design and concept of the study, data collection, initial analysis, design and final submission of the manuscript; PG: Data collection, design and final submission of the manuscript; AK: Initial analysis, revision and final submission of the manuscript; VK will act as guarantor for this paper.
Compliance with Ethical Standards
Conflict of Interest
- 1.Wilkins L, Lewis RA, Klien R, Rosemberg E. The suppression of androgen secretion by cortisone in case of congenital adrenal hyperplasia: preliminary report. Bull Johns Hopkins Hosp. 1950;86:249–52.Google Scholar
- 5.Khadilkar VV, Khadilkar AV, Cole TJ, Sayyad MG. Cross-sectional growth curves for height, weight, body mass index for affluent Indian children. Indian Pediatr. 2009;46:477–89.Google Scholar
- 7.Nwosu B, Lee MM. Evaluation of short and tall stature in children. Am Fam Physician. 2008;78:597–604.Google Scholar
- 8.Dattani MT, Ziaferi VT, Hindmarsh PC. Evaluation of disordered puberty. In: Brook CGD, Clayton P, Brown RS, editors. Brook’s clinical pediatric endocrinology. 6th ed. United Kingdom: Wiley Blackwell; 2009. p. 213–38.Google Scholar
- 10.Gilsasz V, Ratib O. Hand bone age: a digital atlas of skeletal maturity. United Kingdom: Springer; 2011.Google Scholar
- 11.Tanner JM, Healy M, Goldstein H, Cameron N. Assessment of skeletal maturity and prediction of adult height (TW3 method). 3rd ed. London: WB Saunders, Harcourt Publishers Ltd; 2001.Google Scholar
- 12.Miller WL. The adrenal cortex and its disorders. In: Brook CGD, Clayton P, Brown RS, editors. Brook’s clinical pediatric endocrinology. 6th ed. United Kingdom: Wiley Blackwell; 2009. p. 283–325.Google Scholar
- 14.Gueven A, Nurcan Cebeci A, Hancili S. Gonadotropin releasing hormone analog treatment in children with congenital adrenal hyperplasia complicated by central precocious puberty. Hormones (Athens). 2015;14:265–71.Google Scholar
- 20.Grigorescu-Sido A, Bettendorf M, Schulze E, Duncea I, Heinrich U. Growth analysis in patients with 21-hydroxylase deficiency, influence of glucocorticoid dosage, age at diagnosis, phenotype and genotype on growth and height outcome. Horm Res. 2003;60:84–90.Google Scholar
- 25.Frisch H, Waldhauser F, Lebl J, et al. MEWPE- CAH study group. Congenital adrenal hyperplasia: lessons from a multinational study. Horm Res. 2002;57:95–101.Google Scholar